African Swine Fever (ASF) has devastated swine herds across Asia, Europe, and parts of Africa, costing billions in lost production and trade disruptions. The arrival of the first commercial ASF vaccines marked a turning point in the fight against this devastating disease. However, new studies show that even the most promising vaccines have coverage gaps — leaving producers, veterinarians, and policymakers with important decisions to make about disease prevention and risk management.
What the Data Tells Us About ASF Vaccine Coverage
Recent research on current ASF vaccines, including those used in parts of Asia, has revealed both strengths and limitations:
-
Strong protection against major strains: Existing vaccines appear effective against the ASF virus strains responsible for the largest outbreaks in Asia and Eastern Europe.
-
Surprising results with West African strains: Some studies showed partial or full protection against strains outside the original vaccine target range — suggesting cross-protection in certain cases.
-
Hybrid strains remain a major threat: Where hybrid or recombinant ASF viruses have emerged, vaccines showed reduced or no protection. These hybrids develop when different ASF strains mix in the same region or herd, creating viral variants with new genetic profiles.
The key message: ASF isn’t standing still. As the virus evolves, vaccines developed for one strain may not be a perfect fit for the next.
Why Hybrid ASF Strains Are a Game-Changer
Hybrid ASF strains pose a special problem because they often develop genetic changes that bypass the immunity created by existing vaccines. Researchers have found that relying only on genotype classification — essentially the virus’s genetic “family tree” — isn’t enough to predict vaccine performance.
Instead, some scientists recommend focusing on protein profiles or biotypes, since the proteins on the virus surface determine whether a pig’s immune system can recognize and fight it. This shift in thinking could shape the next generation of vaccines, aiming for broader, cross-strain immunity.
The Role of Biosecurity Alongside Vaccination
Even as vaccines advance, biosecurity remains the first line of defense. Hybrid strains, illegal or improperly used vaccines, and gaps in surveillance make it clear that no single tool can control ASF alone.
For producers, this means:
-
Strict on-farm hygiene to prevent the virus from entering barns.
-
Controlled animal movements and quarantines when needed.
-
Accurate diagnostics to identify which strain or hybrid variant may be present.
-
Collaboration with veterinarians to adjust vaccination and biosecurity plans based on regional risks.
A vaccine reduces risk — but biosecurity limits exposure in the first place. Both are essential.
What Producers Should Watch For
-
Vaccine updates: Future vaccines may be designed using broader strain panels or new platforms like subunit or vector-based vaccines to improve cross-protection.
-
Regional strain surveillance: Producers should stay informed about which ASF strains are active in their area, as this affects vaccine performance.
-
Regulatory approval timelines: Different countries may approve vaccines at different speeds, creating uneven access to protection tools.
-
Hybrid strain monitoring: Because hybrids reduce vaccine effectiveness, their early detection will be critical to prevent new outbreaks.
Bottom Line for the Swine Industry
ASF vaccines are a critical step forward in reducing the disease’s global impact, but they are not yet a silver bullet. Hybrid strains, evolving viruses, and the realities of global pig production mean that:
-
Vaccination programs must adapt as the virus changes.
-
Biosecurity practices must remain in full force.
-
Industry leaders should support research into next-generation vaccines designed for broader coverage and faster updates.
The fight against ASF will require multiple layers of defense — vaccines, biosecurity, diagnostics, and rapid response — to protect herds and safeguard the global pork supply chain.
Lead Image Concept
-
Visual: A pig silhouette protected by a shield representing the vaccine, with cracks or gaps where hybrid strains break through.
-
Colors: Red/orange for ASF risk zones, green/blue for vaccine protection.
-
Headline Overlay: “ASF Vaccine Coverage Gaps: Be Prepared. Stay Protected.”
Access the research Journal here
